{"id":17480,"date":"2022-05-27T19:45:30","date_gmt":"2022-05-27T14:15:30","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17480"},"modified":"2022-11-01T11:51:10","modified_gmt":"2022-11-01T06:21:10","slug":"dry-amd-market-outlook","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook","title":{"rendered":"Dry AMD Market: Pegcetacoplan or Zimura, Which Therapy Will Dominate the Market?"},"content":{"rendered":"\n<p>The Dry AMD market is a billion-dollar business opportunity today as around <strong>80\u201390%<\/strong> of individuals are affected by it. As per DelveInsight analysis, there were approximately <strong>34.9 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-age-macular-degeneration-epidemiology-forecast\">cases of Dry AMD<\/a> in 2021. Moreover, in <strong>10\u201315%<\/strong> of patients with Dry AMD, the deterioration is more rapid and extensive, and they suffer significant vision loss due to Geographic Atrophy (GA)\u2014an aggressive form of Dry AMD.&nbsp;<\/p>\n\n\n\n<p>Geographic Atrophy is less prevalent, accounting for <strong>10\u201320%<\/strong> of all cases of legal blindness caused by Age-related Macular Degeneration. In <strong>10-15%<\/strong> of patients with Dry AMD, the deterioration is more rapid and extensive, and they suffer significant vision loss due to Geographic Atrophy. Most companies are currently developing therapies for Geographic Atrophy treatment, pertaining to this. Due to the lack of approved therapies, the first drug to receive regulatory approval can have a <strong>first-mover advantage <\/strong>compared to other <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-age-macular-degeneration-pipeline-insight\">Dry AMD pipeline therapies<\/a>.<\/p>\n\n\n\n<p>Key Dry AMD companies with their lead products such as <strong>Apellis Pharmaceuticals (Pegcetacoplan), Alkeus Pharmaceuticals (ALK-001), Iveric bio (Zimura), Genentech (Roche; RO7171009; RG6147), Ionis Pharmaceuticals\/Roche (IONIS-FB-LRx), Allegro Ophthalmics (Luminate), NGM Biopharmaceuticals (NGM621), Stealth BioTherapeutics (Elamipretide), Regenerative Patch Technologies (CPCB-RPE1), CellCure Neurosciences (OpRegen), Gyroscope Therapeutics (GT005),<\/strong> and others are working on developing a new treatment for Dry AMD.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162621\/Key-Companies-in-the-Dry-AMD-Market.png\" alt=\"Companies in Dry AMD Market\" class=\"wp-image-17483\" width=\"879\" height=\"365\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162621\/Key-Companies-in-the-Dry-AMD-Market.png 879w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162621\/Key-Companies-in-the-Dry-AMD-Market-300x125.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162621\/Key-Companies-in-the-Dry-AMD-Market-150x62.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162621\/Key-Companies-in-the-Dry-AMD-Market-768x319.png 768w\" sizes=\"(max-width: 879px) 100vw, 879px\" \/><figcaption><strong>Leading Players Working in the Dry AMD Market<\/strong><\/figcaption><\/figure>\n\n\n\n<p>The closest rivals and most potential candidates in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-age-macular-degeneration-market\">Dry AMD market<\/a> race are <strong>pegcetacoplan, <\/strong>developed by Apellis Pharmaceutical, and <strong>zimura,<\/strong> developed by Iveric bio. Both these drugs can be seen as a potential treatment to reduce the progression of Geographic Atrophy and will be available soon in the Dry AMD market.&nbsp;<\/p>\n\n\n\n<p><strong>Apellis Pegcetacoplan (formerly known as APL-2)<\/strong> is a synthetic cyclic peptide conjugated to a PEG polymer that binds specifically to C3, effectively blocking all three pathways of complement activation (classical, lectin, and alternative). Besides Geographic Atrophy, pegcetacoplan is also in <strong>Phase III<\/strong> for Cold Agglutinin Disease (CAD), Complement 3 Glomerulopathy (C3G), and Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN). A subcutaneous drug formulation is already approved for <a href=\"https:\/\/www.delveinsight.com\/report-store\/paroxysmal-nocturnal-hemoglobinuria-market\">Paroxysmal Nocturnal Hemoglobinuria (PNH) treatment<\/a>. According to Phase III results at 12 months, the <strong>OAKS study<\/strong> met its primary endpoint, while the <strong>DERBY study<\/strong> failed to meet its primary endpoint.&nbsp;However, Apellis&#8217; chances of getting intravitreal pegcetacoplan approved for Geographic Atrophy improved following an 18-month study in the pivotal <strong>DERBY and OAKS trials<\/strong> in March 2022, indicating a favorable&nbsp;safety profile for&nbsp;Geographic Atrophy secondary to Age-related Macular Degeneration. The reduction in Geographic Atrophy lesion growth improved with monthly pegcetacoplan treatment from <strong>13% to 21%<\/strong> from 0\u20136 to 12\u201318 months. Apart from these two <a href=\"https:\/\/www.delveinsight.com\/blog\/geographic-atrophy-market-size\">Geographic Atrophy trials<\/a>, the company is also conducting another <strong>Phase III trial<\/strong>, an extension study evaluating the long-term safety and efficacy in patients who participated in <strong>Study APL2-103<\/strong> or completed the Dry AMD treatment at Month 24 of either <strong>DERBY or OAKS study.<\/strong><\/p>\n\n\n\n<p>&nbsp;<\/p>\n\n<div style=\"margin-left:-8px\">\n<table style=\"border:none; border-collapse:collapse\" width=\"671\">\n\t<colgroup>\n\t\t<col width=\"112\">\n\t\t<col width=\"92\">\n\t\t<col width=\"108\">\n\t\t<col width=\"67\">\n\t\t<col width=\"174\">\n\t\t<col width=\"118\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td colspan=\"6\" style=\"border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(128, 128, 128); vertical-align: middle; background-color: rgb(53, 104, 166); padding: 0px 8px; width: 112px;\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase III data on Apellis&#8217;s pegcetacoplan<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">12-month Data<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td colspan=\"5\" style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Reduction in Geographic Atrophy lesion growth at 12 months vs. pooled sham<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Enrollment&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Monthly Dose<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">p-<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">value<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Every Other Month Dose<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">p<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">-value<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oaks&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">637<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">22%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0003<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">16%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0052<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Derby&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">621<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">12%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0528<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">11%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.075<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">18-month Data<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td colspan=\"5\" style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Reduction in Geographic Atrophy lesion growth at 18 months vs. pooled sham<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Study<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Enrollment<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Monthly Dose<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">p<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">-value<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Every Other Month Dose<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:italic\"><span style=\"text-decoration:none\">p-<\/span><\/span><\/span><\/span><\/span><\/span><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">value<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oaks&nbsp;&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">637<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">22%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">&lt;0.0001<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">16%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:middle; background-color:#f2f2f2; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0018<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #000000; width:112px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Derby&nbsp;<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:92px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">621<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:108px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">13%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:67px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0245<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:174px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">12%<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #000000; vertical-align:middle; background-color:#ffffff; padding:0px 8px 0px 8px; border-top:1px solid #808080; border-right:1px solid #000000; border-left:1px solid #808080; width:118px\">\n\t\t\t<p style=\"line-height:1.2; text-align:center; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">0.0332<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:32px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Apellis plans to submit an NDA, to the US FDA, in the second quarter of 2022 to approve intravitreal pegcetacoplan for Dry AMD treatment; the submission would be supported by the completed <strong>Phase II and Phase III Dry AMD clinical trials.<\/strong> The company is also planning to begin pre-submission disclosures to the European medicines agency (EMA) in the first quarter of 2022 and submit a marketing authorization application (MAA) to the EMA in the second half of 2022.&nbsp;<\/p>\n\n\n\n<p>On the other hand, <strong>Iveric zimura (avacincaptad pegol)<\/strong> showed a reduction in the mean rate of Geographic Atrophy growth by <strong>28.11%<\/strong> for the <strong>zimura 2 mg<\/strong> group as compared to the corresponding sham control group and <strong>29.97%<\/strong> for the <strong>zimura 4 mg<\/strong> group as compared to the corresponding sham control group over 18 months in <strong>Phase II\/III (GATHER1\/ OPH2003)<\/strong> study. Data from additional <em>post hoc<\/em> analyses were consistent with the primary analysis results. The company has received a written agreement from the US FDA, under a special protocol assessment (SPA), for the overall design of the <strong>Phase III (GATHER2) trial<\/strong>. The company is planning to submit a new drug application (NDA) to the FDA for marketing approval of zimura for Geographic Atrophy treatment if the <strong>GATHER2 data<\/strong> are positive. The company is also planning to initiate a <strong>Phase III clinical trial<\/strong> evaluating zimura for patients with intermediate Age-related Macular Degeneration.&nbsp;However, there can be no guarantee that Iveric&#8217;s second pivotal trial could be a letdown, as Apellis&#8217; was. In Iveric&#8217;s defense, C5 is arguably a more popular and proven target than C3. Iveric is in pole position to confirm that the C5 complement pathway inhibition approach to treating Geographic Atrophy and, more broadly, Age-related Macular Degeneration works. If it succeeds in doing that next year, it will be in pole position for commercialization. Apart from Geographic Atrophy, zimura is also in <strong>Phase II <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/stargardt-disease-stgd-pipeline-insight\"><strong>clinical trials<\/strong> for Stargardt Disease<\/a> \u2013 a market opportunity worth a few hundred million but a potentially significant opportunity to establish further proof-of-concept for zimura&nbsp; and the company&#8217;s gene therapy pipeline. As already mentioned, the addressable markets for Geographic Atrophy and Age-related Macular Degeneration are huge \u2013 zimura, if approved, looks like a guaranteed blockbuster. Moreover, Pegcetacoplan is anticipated to generate over <strong>900 million dollars<\/strong> in revenue in the Dry AMD market by 2032, while zimura could generate over a <strong>billion dollars<\/strong> in the United States Dry AMD market.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-96cdce71-89fa-4a74-9379-b550a436ad35\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-7o560lu-989-\"><rect fill=\"none\" height=\"254\" width=\"418\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-7o560lu-992-\"><rect fill=\"none\" height=\"254\" width=\"418\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-7o560lu-995-\"><rect fill=\"none\" height=\"254\" width=\"418\" x=\"81\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"254\" width=\"418\" x=\"81\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 186.5 71 L 186.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 333.5 71 L 333.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 481.5 71 L 481.5 325\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 81 325.5 L 499 325.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 81 274.5 L 499 274.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 81 223.5 L 499 223.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 81 173.5 L 499 173.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 81 122.5 L 499 122.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 81 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"254\" width=\"418\" x=\"81\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-tick\" d=\"M 186.5 325 L 186.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-tick\" d=\"M 333.5 325 L 333.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-tick\" d=\"M 481.5 325 L 481.5 335\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-axis-line\" d=\"M 81 325.5 L 499 325.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 25.533300399780273 198)\" x=\"25.533300399780273\" y=\"198\">Revenue in USD Million<\/text><path class=\"highcharts-axis-line\" d=\"M 81 71 L 81 325\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" aria-label=\"Zimura, bar series 1 of 2 with 2 bars.\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-7o560lu-992-)\" data-z-index=\"0.1\" opacity=\"1\" role=\"region\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(81,71) scale(1 1)\"><rect aria-label=\"x, 2025, 816. Zimura.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"83\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"100\" x=\"55.5\" y=\"109.5\"><\/rect><rect aria-label=\"x, 2032, 1,224. Zimura.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"125\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"100\" x=\"262.5\" y=\"36.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(81,71) scale(1 1)\"><\/g><g aria-hidden=\"false\" aria-label=\"Pegcetacoplan, bar series 2 of 2 with 2 bars.\" class=\"highcharts-series highcharts-series-1 highcharts-column-series highcharts-color-1\" clip-path=\"url(#highcharts-7o560lu-992-)\" data-z-index=\"0.1\" opacity=\"1\" role=\"region\" style=\"outline: none;\" tabindex=\"-1\" transform=\"translate(81,71) scale(1 1)\"><rect aria-label=\"x, 2025, 612. Pegcetacoplan.\" class=\"highcharts-point highcharts-color-1\" fill=\"#434348\" height=\"62\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"100\" x=\"55.5\" y=\"192.5\"><\/rect><rect aria-label=\"x, 2032, 918. Pegcetacoplan.\" class=\"highcharts-point highcharts-color-1\" fill=\"#434348\" height=\"93\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"100\" x=\"262.5\" y=\"161.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-1 highcharts-column-series highcharts-color-1\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(81,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Dry AMD Market Insights &#8211; 2032<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">DelveInsight&#8217;s Market Size Estimates for Pegcetacoplan and Zimura in the US<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(81,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(90,139)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">816<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>816<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(291,87)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">1 224<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1 224<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-1 highcharts-column-series highcharts-color-1\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(81,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(90,211)\"><text data-z-index=\"1\" style=\"color: rgb(255, 255, 255); font-size: 11px; font-weight: bold; fill: rgb(255, 255, 255);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#000000\" stroke=\"#000000\" stroke-linejoin=\"round\" stroke-width=\"2px\">612<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>612<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-1\" data-z-index=\"1\" transform=\"translate(297,196)\"><text data-z-index=\"1\" style=\"color: rgb(255, 255, 255); font-size: 11px; font-weight: bold; fill: rgb(255, 255, 255);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#000000\" stroke=\"#000000\" stroke-linejoin=\"round\" stroke-width=\"2px\">918<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>918<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-legend highcharts-no-tooltip\" data-z-index=\"7\" transform=\"translate(152,359)\"><rect class=\"highcharts-legend-box\" fill=\"none\" height=\"26\" rx=\"0\" ry=\"0\" width=\"204\" x=\"0\" y=\"0\"><\/rect><g data-z-index=\"1\"><g><g class=\"highcharts-legend-item highcharts-column-series highcharts-color-0 highcharts-series-0\" data-z-index=\"1\" transform=\"translate(8,3)\"><text data-z-index=\"2\" style=\"color: rgb(51, 51, 51); cursor: pointer; font-size: 12px; font-weight: bold; fill: rgb(51, 51, 51);\" text-anchor=\"start\" x=\"21\" y=\"15\">Zimura<\/text><rect class=\"highcharts-point\" data-z-index=\"3\" fill=\"#7cb5ec\" height=\"12\" rx=\"6\" ry=\"6\" width=\"12\" x=\"2\" y=\"4\"><\/rect><\/g><g class=\"highcharts-legend-item highcharts-column-series highcharts-color-1 highcharts-series-1\" data-z-index=\"1\" transform=\"translate(92.08320236206055,3)\"><text data-z-index=\"2\" style=\"color: rgb(51, 51, 51); cursor: pointer; font-size: 12px; font-weight: bold; fill: rgb(51, 51, 51);\" text-anchor=\"start\" x=\"21\" y=\"15\">Pegcetacoplan<\/text><rect class=\"highcharts-point\" data-z-index=\"3\" fill=\"#434348\" height=\"12\" rx=\"6\" ry=\"6\" width=\"12\" x=\"2\" y=\"4\"><\/rect><\/g><\/g><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"186.53465346535\" y=\"344\">2025<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"334.34229137199\" y=\"344\">2030<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"482.14992927864\" y=\"344\">2035<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"329\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"278\">500<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"227\">1000<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"177\">1500<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"126\">2000<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"66\" y=\"75\">2500<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Dry AMD Market Insights - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Dry AMD Market Insights &#8211; 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-7o560lu-995-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Dry AMD Market Insights - 2032\"},\"subtitle\":{\"text\":\"DelveInsight's Market Size Estimates for Pegcetacoplan and Zimura in the US\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"stacking\":\"normal\",\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Zimura\",\"turboThreshold\":0},{\"name\":\"Pegcetacoplan\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Zimura\\\";\\\"Pegcetacoplan\\\"\\n2025;816;612\\n2032;1224;918\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Revenue in USD Million\"}}],\"credits\":{\"text\":\"Dry AMD Market Insights - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/dry-amd-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-96cdce71-89fa-4a74-9379-b550a436ad35\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>As per our estimate, even though pegcetacoplan is expected to launch first in the Dry AMD market, zimura will have the edge over pegcetacoplan. Owning to its compelling efficacy in slowing the growth of Geographic Atrophy lesions with an immaculate safety\/tolerability profile to date. Approval of <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/dry-age-related-macular-degeneration\">therapies for Dry AMD<\/a> is expected to pave the way for exciting novel therapeutic opportunities in the Dry AMD market. The expected entry of these novel Dry AMD therapies with different mechanisms of action may change the treatment regimen of Dry AMD.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/dry-amd-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-1024x256.png\" alt=\"Dry AMD Market Outlook\" class=\"wp-image-17482\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/27162526\/Dry-Age-related-Macular-Degeneration-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><strong>FAQs<\/strong><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1653648475964\"><strong class=\"schema-faq-question\"><strong>1. What is Dry AMD?<\/strong><\/strong> <p class=\"schema-faq-answer\">Dry AMD is a progressive degeneration of the macula cells that occurs over many years as retinal cells die and are not replaced. The term 'dry' does not imply that the individual has dry eyes.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653648489396\"><strong class=\"schema-faq-question\"><strong>2. What are Dry AMD symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Dry AMD symptoms appear gradually and are usually painless. They include visual distortions, reduced central vision in one or both eyes, decreased intensity or brightness of colors, increased blurriness of printed words, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653648499373\"><strong class=\"schema-faq-question\"><strong>3. What are Dry AMD treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">There is currently no Dry AMD treatment available. However, numerous clinical trials are currently underway by several companies to improve the Dry AMD treatment landscape.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653648512787\"><strong class=\"schema-faq-question\"><strong>4. What\u00a0 prevalent is Dry AMD?<\/strong><\/strong> <p class=\"schema-faq-answer\">As per DelveInsight analysis, there were approximately 34.9 million cases of Dry AMD in 2021. These numbers are further expected to increase by 2032.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653648522885\"><strong class=\"schema-faq-question\"><strong>5. Which are the therapies in the Dry AMD pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key therapies in the Dry AMD pipeline include Pegcetacoplan, ALK-001, Zimura, RO7171009, RG6147, IONIS-FB-LRx, Luminate, NGM621, Elamipretide, CPCB-RPE1, OpRegen, GT005<strong>,<\/strong> and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1653648534765\"><strong class=\"schema-faq-question\"><strong>6. Which companies are working in the Dry AMD market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading pharma companies such as Apellis Pharmaceuticals, Alkeus Pharmaceuticals, Iveric bio, Genentech, Ionis Pharmaceuticals, Roche, Allegro Ophthalmics, NGM Biopharmaceuticals, Stealth BioTherapeutics, Regenerative Patch Technologies, CellCure Neurosciences, Gyroscope Therapeutics, and others are working on developing a novel approach to treating Dry AMD.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>The Dry AMD market is a billion-dollar business opportunity today as around 80\u201390% of individuals are affected by it. As per DelveInsight analysis, there were approximately 34.9 million cases of Dry AMD in 2021. Moreover, in 10\u201315% of patients with Dry AMD, the deterioration is more rapid and extensive, and they suffer significant vision loss [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":19506,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1299,19373,19376,19374,19375,19377],"industry":[17225],"therapeutic_areas":[17244],"class_list":["post-17480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-age-related-macular-degeneration","tag-dry-amd","tag-dry-amd-clinical-trials","tag-dry-amd-market","tag-dry-amd-pipeline","tag-dry-amd-treatment","industry-pharmaceutical","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging Therapies in Dry AMD Market | Pegcetacoplan and Zimura<\/title>\n<meta name=\"description\" content=\"The launch of the emerging therapies in the Dry AMD Market such as Pegcetacoplan and Zimura, is anticipated to transform treatment scenario.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging Therapies in Dry AMD Market | Pegcetacoplan and Zimura\" \/>\n<meta property=\"og:description\" content=\"The launch of the emerging therapies in the Dry AMD Market such as Pegcetacoplan and Zimura, is anticipated to transform treatment scenario.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-27T14:15:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-01T06:21:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging Therapies in Dry AMD Market | Pegcetacoplan and Zimura","description":"The launch of the emerging therapies in the Dry AMD Market such as Pegcetacoplan and Zimura, is anticipated to transform treatment scenario.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook","og_locale":"en_US","og_type":"article","og_title":"Emerging Therapies in Dry AMD Market | Pegcetacoplan and Zimura","og_description":"The launch of the emerging therapies in the Dry AMD Market such as Pegcetacoplan and Zimura, is anticipated to transform treatment scenario.","og_url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-05-27T14:15:30+00:00","article_modified_time":"2022-11-01T06:21:10+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook","url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook","name":"Emerging Therapies in Dry AMD Market | Pegcetacoplan and Zimura","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura.png","datePublished":"2022-05-27T14:15:30+00:00","dateModified":"2022-11-01T06:21:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The launch of the emerging therapies in the Dry AMD Market such as Pegcetacoplan and Zimura, is anticipated to transform treatment scenario.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648475964"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648489396"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648499373"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648512787"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648522885"},{"@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648534765"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura.png","width":772,"height":482,"caption":"Dry AMD Emerging Therapies in Therapeutics Market Pegcetacoplan and Zimura"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648475964","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648475964","name":"1. What is Dry AMD?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Dry AMD is a progressive degeneration of the macula cells that occurs over many years as retinal cells die and are not replaced. The term 'dry' does not imply that the individual has dry eyes.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648489396","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648489396","name":"2. What are Dry AMD symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Dry AMD symptoms appear gradually and are usually painless. They include visual distortions, reduced central vision in one or both eyes, decreased intensity or brightness of colors, increased blurriness of printed words, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648499373","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648499373","name":"3. What are Dry AMD treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"There is currently no Dry AMD treatment available. However, numerous clinical trials are currently underway by several companies to improve the Dry AMD treatment landscape.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648512787","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648512787","name":"4. What\u00a0 prevalent is Dry AMD?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"As per DelveInsight analysis, there were approximately 34.9 million cases of Dry AMD in 2021. These numbers are further expected to increase by 2032.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648522885","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648522885","name":"5. Which are the therapies in the Dry AMD pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key therapies in the Dry AMD pipeline include Pegcetacoplan, ALK-001, Zimura, RO7171009, RG6147, IONIS-FB-LRx, Luminate, NGM621, Elamipretide, CPCB-RPE1, OpRegen, GT005<strong>,<\/strong> and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648534765","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/dry-amd-market-outlook#faq-question-1653648534765","name":"6. Which companies are working in the Dry AMD market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading pharma companies such as Apellis Pharmaceuticals, Alkeus Pharmaceuticals, Iveric bio, Genentech, Ionis Pharmaceuticals, Roche, Allegro Ophthalmics, NGM Biopharmaceuticals, Stealth BioTherapeutics, Regenerative Patch Technologies, CellCure Neurosciences, Gyroscope Therapeutics, and others are working on developing a novel approach to treating Dry AMD.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/05\/01115059\/Dry-AMD-Emerging-Therapies-in-Therapeutics-Market-Pegcetacoplan-and-Zimura-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry AMD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry AMD Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry AMD Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry AMD Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Dry AMD Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/span>","<span class=\"advgb-post-tax-term\">Dry AMD<\/span>","<span class=\"advgb-post-tax-term\">Dry AMD Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Dry AMD Market<\/span>","<span class=\"advgb-post-tax-term\">Dry AMD Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Dry AMD Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 27, 2022","modified":"Updated on Nov 1, 2022"},"absolute_dates_time":{"created":"Posted on May 27, 2022 7:45 pm","modified":"Updated on Nov 1, 2022 11:51 am"},"featured_img_caption":"Dry AMD Emerging Therapies in Therapeutics Market Pegcetacoplan and Zimura","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17480"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17480\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19506"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17480"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17480"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}